HomeKYNB • NASDAQ
add
FibroGen Inc
Nakaraang pagsara
$9.50
Sakop ng araw
$9.05 - $9.37
Sakop ng taon
$9.02 - $9.70
Market cap
36.69M USD
Average na Volume
3.49K
P/E ratio
0.17
Dividend yield
-
Primary exchange
NASDAQ
Mga balita tungkol sa merkado
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Set 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | 1.08M | 774.80% |
Gastos sa pagpapatakbo | 5.30M | -43.44% |
Net na kita | 200.64M | 1,274.41% |
Net profit margin | 18.65K | 234.25% |
Kita sa bawat share | 49.61 | 13,491.78% |
EBITDA | -5.18M | 81.77% |
Aktuwal na % ng binabayarang buwis | — | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Set 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 117.98M | -9.94% |
Kabuuang asset | 137.01M | -48.18% |
Kabuuang sagutin | 119.53M | -74.36% |
Kabuuang equity | 17.48M | — |
Natitirang share | 4.05M | — |
Presyo para makapag-book | -2.26 | — |
Return on assets | -8.52% | — |
Return on capital | 52.71% | — |
Cash Flow
Net change in cash
| (USD) | Set 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | 200.64M | 1,274.41% |
Cash mula sa mga operasyon | -1.85M | 77.95% |
Cash mula sa pag-invest | 87.16M | 11,444.37% |
Cash mula sa financing | -85.92M | -67,551.18% |
Net change in cash | -1.87M | 80.78% |
Malayang cash flow | 72.84M | 1,077.84% |
Tungkol
FibroGen, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2025, FibroGen was mainly reduced to a single early-stage oncology drug candidate.
On January 8, 2026, FibroGen changed its name to Kyntra Bio and ticker symbol to KYNB. Wikipedia
Itinatag
Ene 1, 1993
Headquarters
Website
Mga Empleyado
225
